Vertex could snag 250 more Kalydeco patients with EMA nod

Carly Helfand Back in February, the FDA green-lighted Kalydeco to treat cystic fibrosis in patients with one of 8 distinct gating mutations, dramatically ...

Persevering in Eastern Europe despite unrest, Stada eyes more deals

Tracy Staton Trouble in the Ukraine and Russia forced Germany's Stada to cut its earnings forecast two months ago. Now, Stada CEO Hartmut Retzlaff says the company hasn't gone ...

More M&A: Forest snags Furiex for $1.1B as Meda stiff-arms Mylan’s $9B bid

Tracy Staton Pharma's M&A fever may be most obvious among the industry's biggest players, but smaller companies are making their own bids, transformational and otherwise. FiercePharma ...

BMS extends deal with Samsung as its pipeline percolates with more biologics

Eric Palmer With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship ...

Lupin recalls more Suprax on purity problems, adding to Indian pharma’s quality questions

Tracy Staton In the latest black eye for India's pharma industry, Lupin is recalling some 10,000 bottles of its Suprax antibiotic in the U.S. The pills fell short of standards for ...

Vivus needs more than boardroom shuffling to keep up with Arena’s Belviq

Carly Helfand One pre-First Manhattan Co.-settlement Vivus director standing for re-election at the company's annual meeting, that is. The Mountain View, CA-based drugmaker announced ...

Novartis slashing thousands more jobs in global reorganization, shifting many to India

Tracy Staton Novartis' 500 Swiss job cuts announced earlier this month are just the tip of a global iceberg. The company plans to cut or shuffle up to 4,000 jobs in its pharma business, ...

German Merck is among the companies fishing in Iran for more business

Eric Palmer With the prospect of sanctions easing, drugmakers are sizing up the opportunities in Iran, and Merck KGaA and others intend to seize them. FiercePharma News

Ariad returns Iclusig to market but with more restrictions and smaller patient pool

Eric Palmer Ariad Pharmaceuticals is back in the market with Iclusig. The FDA is allowing the Cambridge, MA-based company to again sell the leukemia drug, but with tighter restrictions ...

Continuing Medical Education Deserves More Scrutiny: Study

esilverman At a time when increasing scrutiny is applied to funding for continuing medical education, a new study notes that relatively little is known about medical communications ...

More Pharma Jobs Are Disappearing: Forest And Eisai Cut Back

esilverman Yet another round of cutbacks in the pharmaceutical industry is unfolding. The latest to shrink operations is Forest Laboratories, which is slashing expenses by ...

Argos rakes in $17.5M more to wrap up PhIII for cancer drug

Damian Garde Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get ...
Page 3 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS